

ABSTRACT CITATION ID: NOAE064.673

OTHR-02. ONE-YEAR FOLLOW-UP OF THE NEW ERN PAEDCAN
CNS TUMOR BOARD: LESSONS LEARNT AND FUTURE
PROSPECTS

Marthe Sönksen¹, Brigitte Bison^{2,3}, Lisa Bußenius¹, Jelena Rascon⁴,
Denise Obrecht-Sturm¹, Barry Pizer⁵, Katrin Scheinemann^{6,7},
Martin Schalling⁸, Ruth Ladenstein⁸, Martin Mynarek¹, Stefan Rutkowski¹;
¹Pediatric Hematology and Oncology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, ²Diagnostic and Interventional
Neuroradiology, Faculty of Medicine, University of Augsburg, Augsburg,
Germany, ³Neuroradiological Reference Center for the Pediatric Brain
Tumor (HIT) Studies of the German Society of Pediatric Oncology and
Hematology, Faculty of Medicine, University of Augsburg, Augsburg,
Germany, ⁴Center for Pediatric Oncology and Hematology, Vilnius
University Hospital Santaros Klinikos, Vilnius, Lithuania, ⁵Department
of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust,
Liverpool, United Kingdom, ⁶Pediatric Hematology-Oncology Center,
Children's Hospital of Eastern Switzerland, St Gallen, Switzerland, ⁷Faculty
of Health Science and Medicine, University Lucerne, Lucerne, Switzerland,
⁸St Anna Children's Cancer Research Institute CCRI, Vienna, Austria

BACKGROUND: European Reference Networks (ERN) are collaborative networks connecting healthcare professionals across Europe. A virtual tumor board for pediatric patients with central nervous system (CNS) tumors was established within the ERN for pediatric oncology (ERN PaedCan) in September 2022. We report the feasibility, the implementation of recommendations and satisfaction of the participants. **METHODS:** A web-based questionnaire was distributed to physicians presenting cases between November 2022 and November 2023. Questions addressed the implementation of recommendations, satisfaction and basic information about the local institution. Basic data of the presented cases were taken from anonymized tumor board protocols. **RESULTS:** In the first year, 19 patients from 11 institutions located in nine European countries were discussed in 21 tumor boards. Median age at diagnosis was 10 (1-17) years. Demonstration of MRI findings by the German national reference center for neuroradiology was conducted in 19/21 conferences. 18/21 questionnaires (86%) were answered by physicians from eight countries. Main reason to request the discussion were questions about therapy (78%, n=14/18). Inquiring institutions treated a median of 10 (5-150) neuro-oncological pediatric patients per year. All hospitals conducted own institutional tumor boards. National central review was available in 3/8 countries (38%). Recommendations were followed, at least partly, in all cases except for one patient experiencing unexpected clinical deterioration. Recommendations were deemed helpful in 89%. All participants would recommend the tumor board to colleagues. Technical issues regarding data provision were reported as the main obstacle in 50%. **CONCLUSIONS:** A European virtual tumor board for pediatric patients with CNS tumors is feasible and perceived as useful by the participating institutions. Recommendations were followed frequently. Optimization of privacy-compliant data exchange is crucial for continuance of the format. This project has been supported by ERN PaedCan, which is funded by the European Union within the EU4Health Program 2021-2027. Funded by EU-grant 101085543.